GU Cancers 2020 | SIP-T: autologous T-cells for prostate cancer

Daniel Petrylak

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses the association between humoral antigen spread with cytotoxic T lymphocyte activity after sipuleucel-T (SIP-T) treatment in two Phase II clinical studies: STAMP and STRIDE. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter